Efficacy of probiotic Bacillus licheniformis DSM 28710 on performance and the mitigation of Clostridium perfringens-induced necrotic enteritis in broiler chickens

Abstract

The aim of this study was to evaluate the impact of a probiotic Bacillus licheniformis strain (DSM 28710; B-Act®) on growth performance and its capacity to mitigate necrotic enteritis (NE; induced via a Clostridium perfringens challenge) in poultry. A broiler trial was conducted, examining three treatments for 42 days under an induced NE challenge; a negative control (basal diet only); an antibiotic treated group (oxytetracycline hydrochloride (OXT), therapeutic dose of 105 mg OXT/litre in drinking water, for three days after C. perfringens challenge); and a B-Act group (500 g B-Act/tonne of feed, equalling 1.6×1012 colony forming units B. licheniformis DSM 28710/tonne of feed, supplemented from start until finish). Despite the induced NE challenge, weight gains of the B-Act and OXT groups were similar to each other but significantly higher compared to the control at the end of the study (P<0.05). Weight gain of the B-Act group was already significantly higher compared to the control on day 21 (P<0.05), indicating a potential benefit of the probiotic even before clinical establishment of NE. Feed conversion ratio (FCR) values followed a similar pattern throughout the study, with a significantly lower overall FCR for the B-Act and OXT groups compared to the control (P<0.05; d0-42). Birds fed B-Act had significantly (P<0.05) lower NE lesions compared to the control and OXT group on day 21, although OXT was not supplemented to the animals at this stage yet. Both B-Act and OXT groups had significantly (P<0.05) lower NE scores than the control on day 28, demonstrating the effectiveness of the antibiotic treatment and the mitigating effect of B-Act on the effects of a Clostridium perfringens induced NE challenge.